Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Return on Invested Capital (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Return on Invested Capital data on record, last reported at 0.03% in Q3 2025.

  • For Q3 2025, Return on Invested Capital rose 63.0% year-over-year to 0.03%; the TTM value through Sep 2025 reached 0.03%, up 63.0%, while the annual FY2024 figure was 0.42%, N/A changed from the prior year.
  • Return on Invested Capital reached 0.03% in Q3 2025 per GLUE's latest filing, down from 0.05% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.05% in Q2 2025 and bottomed at 0.87% in Q1 2024.
  • Average Return on Invested Capital over 3 years is 0.42%, with a median of 0.5% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: skyrocketed 40bps in 2024, then surged 87bps in 2025.
  • A 3-year view of Return on Invested Capital shows it stood at 0.79% in 2023, then skyrocketed by 50bps to 0.39% in 2024, then soared by 108bps to 0.03% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Invested Capital were 0.03% in Q3 2025, 0.05% in Q2 2025, and 0.01% in Q1 2025.